ITGAM and renal fibrosis: Targeting specific immune cells, like reducing CD33dim HLA DR + CD11b + AC MDSCs to lower renal fibrosis risk and inhibiting granzyme A (GZMA) in NK cells to reduce inflammation, shows promise.